InflaRx Shares Rally on Plans to Seek FDA Emergency-Use Authorization for Vilobelimab

By Colin Kellaher

Shares of InflaRx NV rose more than 20% on Tuesday after the clinical-stage biopharmaceutical company outlined plans to seek U.S. Food and Drug Administration emergency-use authorization for its investigational drug vilobelimab in patients with severe Covid-19.

The Jena, Germany-based company said that following a meeting with the FDA to discuss a potential submission and the development of vilobelimab in mechanically ventilated Covid-19 patients, it plans to submit its request for an emergency-use authorization by the end of the third quarter.

InflaRx in late March said the Phase 3 portion of a Phase 2/3 study of vilobelimab in mechanically ventilated Covid-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9%, which the company said was encouraging but not statistically significant under the study's prespecified primary endpoint.

InflaRx shares were recently changing hands at $1.68, up 21%.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 26, 2022 10:37 ET (14:37 GMT)

InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2024 to May 2024